Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls
Authors:
Top Cited Papers
Open Access
- 20 September 2022
- journal article
- research article
- Published by Elsevier in Gastroenterology
- Vol. 163 (6) , 1630-1642.e3
Abstract
No abstract availableKeywords
Funding Information
- Newcastle upon Tyne Hospitals NHS Foundation Trust
- Oxford University Hospitals NHS Foundation Trust
- Betsi Cadwaladr University Health Board
- Intercept Pharmaceuticals
This publication has 24 references indexed in Scilit:
- EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitisJournal of Hepatology, 2017
- Long‐term clinical impact and cost‐effectiveness of obeticholic acid for the treatment of primary biliary cholangitisHepatology, 2017
- A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary CholangitisNew England Journal of Medicine, 2016
- The UK‐PBC risk scores: Derivation and validation of a scoring system for long‐term prediction of end‐stage liver disease in primary biliary cholangitisHepatology, 2015
- Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up StudyGastroenterology, 2014
- Use of Stabilized Inverse Propensity Scores as Weights to Directly Estimate Relative Risk and Its Confidence IntervalsValue in Health, 2010
- Primary biliary cirrhosisSeminars in Immunopathology, 2009
- The battle of HelsinkiEMBO Reports, 2006
- Bias reduction of maximum likelihood estimatesBiometrika, 1993
- A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary CirrhosisNew England Journal of Medicine, 1991